Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


8 Ann Intern Med
4 Antimicrob Agents Chemother
2 BMC Pediatr
25 BMJ
1 Drug Saf
2 Drugs
4 Epidemiol Infect
1 Eur J Epidemiol
7 J Clin Microbiol
1 J Immunol
7 J Virol
5 J Virol Methods
1 Lancet
3 MMWR Morb Mortal Wkly Rep
11 N Engl J Med
1 PLoS Biol
1 PLoS Comput Biol
4 PLoS Med
52 PLoS One
10 Proc Natl Acad Sci U S A
25 Vaccine
4 Virology
3 Virus Res

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Intern Med

    ESCMID recommendations for COVID-19 testing in asymptomatic persons to prevent transmission in health care.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/J22-0043.
    PubMed         Abstract available

  2. ATHALE J, Danner RL
    In critically ill patients with COVID-19, antiplatelet therapy did not increase organ support-free days at 21 d.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/J22-0046.
    PubMed         Abstract available

    COVID-19 diagnosis, but not vaccination, was linked to increased risk for immune-mediated neurologic events.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/J22-0048.
    PubMed         Abstract available

  4. MEHTA A, Bansal M, Vallabhajosyula S
    In COVID-19 acute hypoxemic respiratory failure, awake prone positioning vs. the supine position reduces intubations.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/J22-0050.
    PubMed         Abstract available

  5. LAINE C, Cotton D
    Care of Patients With New, Continuing, or Recurring Symptoms After Acute SARS-CoV-2 Infection.
    Ann Intern Med. 2022 May 27. doi: 10.7326/M22-1636.

  6. HOPE AA
    Understanding and Improving Recovery From COVID-19.
    Ann Intern Med. 2022 May 24. doi: 10.7326/M22-1492.

  7. SNELLER MC, Liang CJ, Marques AR, Chung JY, et al
    A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings.
    Ann Intern Med. 2022 May 24. doi: 10.7326/M21-4905.
    PubMed         Abstract available

  8. ZAHRADKA I, Petr V, Modos I, Magicova M, et al
    Association Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients : A Registry-Based Report.
    Ann Intern Med. 2022 May 3. doi: 10.7326/M21-2973.
    PubMed         Abstract available

    Antimicrob Agents Chemother

  9. RODVOLD KA, Gotfried MH, Gupta V, Ek A, et al
    Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects.
    Antimicrob Agents Chemother. 2022;66:e0059022.
    PubMed         Abstract available

  10. WATSON JA, Kissler SM, Day NPJ, Grad YH, et al
    Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies.
    Antimicrob Agents Chemother. 2022;66:e0019222.
    PubMed         Abstract available

  11. CHECKMAHOMED L, Carbonneau J, Du Pont V, Riola NC, et al
    In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.
    Antimicrob Agents Chemother. 2022;66:e0019822.
    PubMed         Abstract available

  12. ICHO S, Rujas E, Muthuraman K, Tam J, et al
    Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells.
    Antimicrob Agents Chemother. 2022;66:e0043922.
    PubMed         Abstract available

    BMC Pediatr

  13. CHAN M, Mokiao R, Wilson AC, Pottanat N, et al
    Food insecurity during COVID-19 in children with end-stage kidney disease: a pilot study.
    BMC Pediatr. 2022;22:420.
    PubMed         Abstract available

  14. GULU M, Yapici H, Mainer-Pardos E, Alves AR, et al
    Investigation of obesity, eating behaviors and physical activity levels living in rural and urban areas during the covid-19 pandemic era: a study of Turkish adolescent.
    BMC Pediatr. 2022;22:405.
    PubMed         Abstract available


  15. MAHASE E
    Covid-19: Recovery trial set to lose funding as proposal to examine flu drugs is rejected.
    BMJ. 2022;378:o1809.

  16. WILLIAMS S, Michie S
    Covid-19: One year on from "Freedom Day," what have we learnt?
    BMJ. 2022;378:o1803.

  17. Long covid and apheresis: a miracle cure sold on a hypothesis of hope.
    BMJ. 2022;378:o1813.

  18. SAGE I
    A seven point plan to suppress covid infections and reduce disruptions.
    BMJ. 2022;378:o1793.

  19. JONAS A
    Impact of vaping on respiratory health.
    BMJ. 2022;378:e065997.
    PubMed         Abstract available

  20. TANNE JH
    Covid-19: BA.5 variant is now dominant in US as infections rise.
    BMJ. 2022;378:o1770.

  21. HORNE EMF, Hulme WJ, Keogh RH, Palmer TM, et al
    Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.
    BMJ. 2022;378:e071249.
    PubMed         Abstract available

  22. DYER C
    Covid-19: Up to pound2.7bn of public money at risk from PPE disputes, says watchdog.
    BMJ. 2022;378:o1817.

  23. POPLE D, Monk EJM, Evans S, Foulkes S, et al
    Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model.
    BMJ. 2022;378:e070379.
    PubMed         Abstract available

    Rapid covid-19 vaccination for health workers.
    BMJ. 2022;378:o1674.

  25. HULME WJ, Williamson EJ, Green ACA, Bhaskaran K, et al
    Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY.
    BMJ. 2022;378:e068946.
    PubMed         Abstract available

  26. MCCAY L
    Covid continues to disrupt: what is the plan to deal with it?
    BMJ. 2022;378:o1780.

  27. MCLELLAN A, Abbasi K
    The NHS is not living with covid, it's dying from it.
    BMJ. 2022;378:o1779.

  28. MAHASE E
    Covid-19: High prevalence and lack of hospital beds putting "intense pressure" on ambulances.
    BMJ. 2022;378:o1763.

  29. TANNE JH
    Covid-19: Antimicrobial resistance rose dangerously in US during pandemic, CDC says.
    BMJ. 2022;378:o1755.

  30. OLIVER D
    David Oliver: Covid-19 and the Dunning-Kruger effect.
    BMJ. 2022;378:o1701.

  31. Update to living WHO guideline on drugs for covid-19.
    BMJ. 2022;378:o1713.

  32. ANDERSSON NW, Thiesson EM, Laursen MV, Mogensen SH, et al
    Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
    BMJ. 2022;378:e070483.
    PubMed         Abstract available

  33. WISE J
    Covid-19: MPs call for greater efforts to reach the unvaccinated and partially vaccinated.
    BMJ. 2022;378:o1743.

  34. Update to living systematic review on drug treatments for covid-19.
    BMJ. 2022;378:o1717.

  35. PILLAY J, Gaudet L, Wingert A, Bialy L, et al
    Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
    BMJ. 2022;378:e069445.
    PubMed         Abstract available

  36. DE JONG VMT, Rousset RZ, Antonio-Villa NE, Buenen AG, et al
    Clinical prediction models for mortality in patients with covid-19: external validation and individual participant data meta-analysis.
    BMJ. 2022;378:e069881.
    PubMed         Abstract available

  37. DAVIES M
    Long covid patients travel abroad for expensive and experimental "blood washing".
    BMJ. 2022;378:o1671.

  38. BLOCK J
    Covid-19: Researchers face wait for patient level data from Pfizer and Moderna vaccine trials.
    BMJ. 2022;378:o1731.

    Covid-19: Parts of England see hospital admissions more than double in two weeks.
    BMJ. 2022;378:o1723.

    Drug Saf

  40. HARPAZ R, DuMouchel W, Van Manen R, Nip A, et al
    Signaling COVID-19 Vaccine Adverse Events.
    Drug Saf. 2022;45:765-780.
    PubMed         Abstract available


  41. KEAM SJ
    Tixagevimab + Cilgavimab: First Approval.
    Drugs. 2022;82:1001-1010.
    PubMed         Abstract available

  42. KOUFAKIS T, Mustafa OG, Ajjan RA, Garcia-Moll X, et al
    From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients.
    Drugs. 2022;82:949-955.
    PubMed         Abstract available

    Epidemiol Infect

  43. BREWER TF, Zhang M, Gordon D, Chung RY, et al
    Housing, sanitation and living conditions affecting SARS-CoV-2 prevention interventions in 54 African countries.
    Epidemiol Infect. 2021;149:e183.
    PubMed         Abstract available

  44. PRICE O, Birrell FA, Mifsud EJ, Sullivan SG, et al
    Epidemiology of repeat influenza infection in Queensland, Australia, 2005-2017.
    Epidemiol Infect. 2022 Jul 18:1-19. doi: 10.1017/S0950268822001157.

  45. DE MARCO VERISSIMO C, Lopez Corrales J, Dorey AL, Cwiklinski K, et al
    Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system.
    Epidemiol Infect. 2022;150:e128.
    PubMed         Abstract available

  46. ADAMSON JP, Smith C, Pacchiarini N, Connor TR, et al
    A large outbreak of COVID-19 in a UK prison, October 2020 to April 2021.
    Epidemiol Infect. 2022;150:e134.
    PubMed         Abstract available

    Eur J Epidemiol

  47. NARRES M, Claessen H, Kvitkina T, Rosenbauer J, et al
    Hospitalisation rate and mortality among people with and without diabetes during the COVID-19 pandemic year 2020.
    Eur J Epidemiol. 2022;37:587-590.
    PubMed         Abstract available

    J Clin Microbiol

  48. LAI E, Kennedy EB, Lozach J, Hayashibara K, et al
    A Method for Variant Agnostic Detection of SARS-CoV-2, Rapid Monitoring of Circulating Variants, and Early Detection of Emergent Variants Such as Omicron.
    J Clin Microbiol. 2022;60:e0034222.
    PubMed         Abstract available

  49. FASCHING CL, Servellita V, McKay B, Nagesh V, et al
    COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme.
    J Clin Microbiol. 2022;60:e0026122.
    PubMed         Abstract available

  50. ROBINSON ML, Mirza A, Gallagher N, Boudreau A, et al
    Limitations of Molecular and Antigen Test Performance for SARS-CoV-2 in Symptomatic and Asymptomatic COVID-19 Contacts.
    J Clin Microbiol. 2022;60:e0018722.
    PubMed         Abstract available

  51. GASTON DC, Miller HB, Fissel JA, Jacobs E, et al
    Evaluation of Metagenomic and Targeted Next-Generation Sequencing Workflows for Detection of Respiratory Pathogens from Bronchoalveolar Lavage Fluid Specimens.
    J Clin Microbiol. 2022;60:e0052622.
    PubMed         Abstract available

  52. WEIDMANN MD, Berry GJ, Zucker JE, Huang S, et al
    Bacterial Pneumonia and Respiratory Culture Utilization among Hospitalized Patients with and without COVID-19 in a New York City Hospital.
    J Clin Microbiol. 2022;60:e0017422.
    PubMed         Abstract available

  53. LICHTENEGGER S, Saiger S, Hardt M, Kulnik S, et al
    Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout.
    J Clin Microbiol. 2022;60:e0037622.
    PubMed         Abstract available

  54. DOERN CD, Miller MB, Alby K, Bachman MA, et al
    Proceedings of the Clinical Microbiology Open 2018 and 2019 - a Discussion about Emerging Trends, Challenges, and the Future of Clinical Microbiology.
    J Clin Microbiol. 2022;60:e0009222.
    PubMed         Abstract available

    J Immunol

  55. PEREZ MM, Pimentel VE, Fuzo CA, da Silva-Neto PV, et al
    Acetylcholine, Fatty Acids, and Lipid Mediators Are Linked to COVID-19 Severity.
    J Immunol. 2022;209:250-261.
    PubMed         Abstract available

    J Virol

  56. HAMELE CE, Russell AB, Heaton NS
    In Vivo Profiling of Individual Multiciliated Cells during Acute Influenza A Virus Infection.
    J Virol. 2022 Jul 6:e0050522. doi: 10.1128/jvi.00505.
    PubMed         Abstract available

  57. KAMIKI H, Murakami S, Nishikaze T, Hiono T, et al
    Influenza A Virus Agnostic Receptor Tropism Revealed Using a Novel Biological System with Terminal Sialic Acid Knockout Cells.
    J Virol. 2022 Jul 18:e0041622. doi: 10.1128/jvi.00416.
    PubMed         Abstract available

  58. CHAPARIAN RR, Harding AT, Hamele CE, Riebe K, et al
    A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.
    J Virol. 2022 Jul 12:e0068922. doi: 10.1128/jvi.00689.
    PubMed         Abstract available

  59. YOUK S, Leyson C, Killian ML, Torchetti MK, et al
    Evolution of the North American Lineage H7 Avian Influenza Viruses in Association with H7 Virus's Introduction to Poultry.
    J Virol. 2022 Jul 7:e0027822. doi: 10.1128/jvi.00278.
    PubMed         Abstract available

  60. OISHI K, Horiuchi S, Minkoff JM, tenOever BR, et al
    The Host Response to Influenza A Virus Interferes with SARS-CoV-2 Replication during Coinfection.
    J Virol. 2022 Jul 12:e0076522. doi: 10.1128/jvi.00765.
    PubMed         Abstract available

  61. VAN DE VEN K, van Dijken H, Du W, de Heij F, et al
    Varying Viral Replication and Disease Profiles of H2N2 Influenza in Ferrets Is Associated with Virus Isolate and Inoculation Route.
    J Virol. 2022 Jul 11:e0073222. doi: 10.1128/jvi.00732.
    PubMed         Abstract available

  62. HUI X, Cao L, Xu T, Zhao L, et al
    PSMD12-Mediated M1 Ubiquitination of Influenza A Virus at K102 Regulates Viral Replication.
    J Virol. 2022 Jul 21:e0078622. doi: 10.1128/jvi.00786.
    PubMed         Abstract available

    J Virol Methods

  63. MATEFO L, Cloete VV, Armand BP, Dominique G, et al
    Validation of laboratory developed serology assays for detection of IgG antibody to severe acute respiratory syndrome coronavirus 2 in the South African population.
    J Virol Methods. 2022;307:114571.
    PubMed         Abstract available

  64. AYADI W, Taktak A, Gargouri S, Smaoui F, et al
    Development of a simple genotyping method based on indel mutations to rapidly screen SARS-CoV-2 circulating variants: Delta, Omicron BA.1 and BA.2.
    J Virol Methods. 2022;307:114570.
    PubMed         Abstract available

  65. ADAMS O, Andree M, Hermsen D, Lubke N, et al
    Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts.
    J Virol Methods. 2022;307:114569.
    PubMed         Abstract available

  66. HONG Y, Guo H, Wei M, Zhang Y, et al
    Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein.
    J Virol Methods. 2022;307:114564.
    PubMed         Abstract available

  67. PABBARAJU K, Zelyas N, Wong A, Croxen MA, et al
    Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern.
    J Virol Methods. 2022;307:114553.
    PubMed         Abstract available


  68. WEBER E, Van Buren N, Cunningham T
    COVID-19 ARDS and Posttraumatic Stress Disorder in Family Members After ICU Discharge.
    JAMA. 2022;328:301-302.

  69. LIN HY, Chen MH, Liang CS
    COVID-19 ARDS and Posttraumatic Stress Disorder in Family Members After ICU Discharge.
    JAMA. 2022;328:301.

  70. KENIK J
    Remote Patient Monitoring During COVID-19.
    JAMA. 2022;328:302-303.

  71. AZOULAY E, Pochard F, Kentish-Barnes N
    COVID-19 ARDS and Posttraumatic Stress Disorder in Family Members After ICU Discharge-Reply.
    JAMA. 2022;328:302.

  72. PRONOVOST PJ, Cole MD, Hughes RM
    Remote Patient Monitoring During COVID-19-Reply.
    JAMA. 2022;328:303-304.

    Mix-and-Match COVID-19 Boosters After Inactivated Virus Vaccine.
    JAMA. 2022;328:234.

  74. ABBASI J
    COVID-19 mRNA Vaccine Booster During Pregnancy Increases Maternal and Fetal Antibodies.
    JAMA. 2022 Jun 22. pii: 2793740. doi: 10.1001/jama.2022.11145.

  75. KLOMPAS M, Pandolfi MC, Nisar AB, Baker MA, et al
    Association of Omicron vs Wild-type SARS-CoV-2 Variants With Hospital-Onset SARS-CoV-2 Infections in a US Regional Hospital System.
    JAMA. 2022 Jun 15. pii: 2793582. doi: 10.1001/jama.2022.9609.

  76. JONES JM, Opsomer JD, Stone M, Benoit T, et al
    Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021.
    JAMA. 2022 Jun 13. pii: 2793517. doi: 10.1001/jama.2022.9745.

  77. DOWELL D, Lindsley WG, Brooks JT
    Reducing SARS-CoV-2 in Shared Indoor Air.
    JAMA. 2022 Jun 7. pii: 2793289. doi: 10.1001/jama.2022.9970.

  78. TAI CG, Maragakis LL, Connolly S, DiFiori J, et al
    Association Between COVID-19 Booster Vaccination and Omicron Infection in a Highly Vaccinated Cohort of Players and Staff in the National Basketball Association.
    JAMA. 2022 Jun 2. pii: 2793169. doi: 10.1001/jama.2022.9479.


  79. WOLTER N, Jassat W, von Gottberg A, Cohen C, et al
    Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa.
    Lancet. 2022;400:93-96.

    MMWR Morb Mortal Wkly Rep

  80. MERCED-MORALES A, Daly P, Abd Elal AI, Ajayi N, et al
    Influenza Activity and Composition of the 2022-23 Influenza Vaccine - United States, 2021-22 Season.
    MMWR Morb Mortal Wkly Rep. 2022;71:913-919.
    PubMed         Abstract available

  81. TRAUB AM, Medley A, Gross J, Sloan M, et al
    Pediatric HIV Case Identification Across 22 PEPFAR-Supported Countries During the COVID-19 Pandemic, October 2019-September 2020.
    MMWR Morb Mortal Wkly Rep. 2022;71:894-898.
    PubMed         Abstract available

  82. HAUSE AM, Baggs J, Marquez P, Abara WE, et al
    Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged >/=12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:899-903.
    PubMed         Abstract available

    N Engl J Med

  83. RUBIN EJ, Baden LR, Jha A, Morrissey S, et al
    Audio Interview: A Look at the U.S. Government's Covid-19 Strategy.
    N Engl J Med. 2022;387:e11.

  84. RUBIN EJ, Baden LR, Marks P, Morrissey S, et al
    Audio Interview: Covid-19 Vaccines and the FDA.
    N Engl J Med. 2022;387:e10.

  85. ZHAO X, Zhang R, Qiao S, Wang X, et al
    Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines.
    N Engl J Med. 2022 Jul 6. doi: 10.1056/NEJMc2206900.

  86. WAXMAN JG, Magen O, Hernan MA
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine. Reply.
    N Engl J Med. 2022;387.

  87. TUMMINIA A, Romano M
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2022;387.

  88. COHEN-STAVI CJ, Magen O, Barda N, Yaron S, et al
    BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMoa2205011.
    PubMed         Abstract available

  89. BOUCAU J, Marino C, Regan J, Uddin R, et al
    Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMc2202092.

  90. DESILVA M, Haapala J, Vazquez-Benitez G, Vesco KK, et al
    Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMc2205276.

  91. HALASA NB, Olson SM, Staat MA, Newhams MM, et al
    Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMoa2204399.
    PubMed         Abstract available

  92. RASMUSSEN SA, Jamieson DJ
    Covid-19 Vaccination during Pregnancy - Two for the Price of One.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMe2206730.

  93. SAVILLE M, Cramer JP, Downham M, Hacker A, et al
    Delivering Pandemic Vaccines in 100 Days - What Will It Take?
    N Engl J Med. 2022 Mar 2. doi: 10.1056/NEJMp2202669.

    PLoS Biol

  94. BUSNADIEGO I, Abela IA, Frey PM, Hofmaenner DA, et al
    Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease.
    PLoS Biol. 2022;20:e3001709.
    PubMed         Abstract available

    PLoS Comput Biol

  95. LEMAITRE JC, Pasetto D, Zanon M, Bertuzzo E, et al
    Optimal control of the spatial allocation of COVID-19 vaccines: Italy as a case study.
    PLoS Comput Biol. 2022;18:e1010237.
    PubMed         Abstract available

    PLoS Med

  96. REZEL-POTTS E, Douiri A, Sun X, Chowienczyk PJ, et al
    Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK.
    PLoS Med. 2022;19:e1004052.
    PubMed         Abstract available

  97. COBB NL, Collier S, Attia EF, Augusto O, et al
    Global influenza surveillance systems to detect the spread of influenza-negative influenza-like illness during the COVID-19 pandemic: Time series outlier analyses from 2015-2020.
    PLoS Med. 2022;19:e1004035.
    PubMed         Abstract available

  98. SHIBUYA K, Tan CC, Chun AY, Leung GM, et al
    Global human security in the post-COVID-19 era: The rising role of East Asia.
    PLoS Med. 2022;19:e1003939.
    PubMed         Abstract available

  99. GRAIS RF, Baron E
    Addressing the impacts of COVID-19 on refugee health.
    PLoS Med. 2022;19:e1004050.

    PLoS One

  100. CARPALLO-PORCAR B, Romo-Calvo L, Perez-Palomares S, Jimenez-Sanchez C, et al
    Efficacy of an asynchronous telerehabilitation program in post-COVID-19 patients: A protocol for a pilot randomized controlled trial.
    PLoS One. 2022;17:e0270766.
    PubMed         Abstract available

  101. WINTER T, Jose PE, Riordan BC, Bizumic B, et al
    Left-wing support of authoritarian submission to protect against societal threat.
    PLoS One. 2022;17:e0269930.
    PubMed         Abstract available

  102. ZHANG A, Li D, Song C, Jing H, et al
    Evaluation of different combination of pam2CSK4, poly (I:C) and imiquimod enhance immune responses to H9N2 avian influenza antigen in dendritic cells and duck.
    PLoS One. 2022;17:e0271746.
    PubMed         Abstract available

  103. ABU-RADDAD LJ, Dargham S, Chemaitelly H, Coyle P, et al
    COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar.
    PLoS One. 2022;17:e0271324.
    PubMed         Abstract available

  104. DEMOULE A, Fartoukh M, Louis G, Azoulay E, et al
    ICU strain and outcome in COVID-19 patients-A multicenter retrospective observational study.
    PLoS One. 2022;17:e0271358.
    PubMed         Abstract available

  105. BENDARDAF R, Bhamidimarri PM, Al-Abadla Z, Zein D, et al
    Ferritin, blood urea nitrogen, and high chest CT score determines ICU admission in COVID-19 positive UAE patients: A single center retrospective study.
    PLoS One. 2022;17:e0269185.
    PubMed         Abstract available

  106. RAHIMI-LEVENE N, Shapira J, Tzur I, Shiloah E, et al
    Predictors of mortality in COVID-19 patients treated with convalescent plasma therapy.
    PLoS One. 2022;17:e0271036.
    PubMed         Abstract available

  107. ABUHAMMAD S, Khabour OF, Alzoubi KH, Hamaideh S, et al
    The public's attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan.
    PLoS One. 2022;17:e0271625.
    PubMed         Abstract available

  108. LIANG C, Ogilvie RP, Doherty M, Clifford CR, et al
    Trends in COVID-19 patient characteristics in a large electronic health record database in the United States: A cohort study.
    PLoS One. 2022;17:e0271501.
    PubMed         Abstract available

  109. FALLACH N, Segal Y, Agassy J, Perez G, et al
    Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study.
    PLoS One. 2022;17:e0270893.
    PubMed         Abstract available

  110. HUNG CC, Banerjee S, Gilada I, Green K, et al
    Impact of COVID-19 on the HIV care continuum in Asia: Insights from people living with HIV, key populations, and HIV healthcare providers.
    PLoS One. 2022;17:e0270831.
    PubMed         Abstract available

  111. BHARDWAJ V, Dela Cruz M, Subramanyam D, Kumar R, et al
    Exercise-induced myokines downregulates the ACE2 level in bronchial epithelial cells: Implications for SARS-CoV-2 prevention.
    PLoS One. 2022;17:e0271303.
    PubMed         Abstract available

  112. KLINK GV, Safina KR, Garushyants SK, Moldovan M, et al
    Spread of endemic SARS-CoV-2 lineages in Russia before April 2021.
    PLoS One. 2022;17:e0270717.
    PubMed         Abstract available

  113. MAYA S, Kahn JG, Lin TK, Jacobs LM, et al
    Indirect COVID-19 health effects and potential mitigating interventions: Cost-effectiveness framework.
    PLoS One. 2022;17:e0271523.
    PubMed         Abstract available

  114. HILBERT K, Boeken O, Asbrand J, Seemann S, et al
    Who is seeking help for psychological distress associated with the COVID-19 pandemic? Characterization of risk factors in 1269 participants accessing low-threshold psychological help.
    PLoS One. 2022;17:e0271468.
    PubMed         Abstract available

  115. ROBERTSON JL, Senger RS, Talty J, Du P, et al
    Alterations in the molecular composition of COVID-19 patient urine, detected using Raman spectroscopic/computational analysis.
    PLoS One. 2022;17:e0270914.
    PubMed         Abstract available

  116. LEITAO C, Shumba J, Quinn M
    Perspectives and experiences of Covid-19: Two Irish studies of families in disadvantaged communities.
    PLoS One. 2022;17:e0270472.
    PubMed         Abstract available

  117. BUDANUR NB, Hof B
    An autonomous compartmental model for accelerating epidemics.
    PLoS One. 2022;17:e0269975.
    PubMed         Abstract available

  118. POUDEL R, Daniels LB, DeFilippis AP, Hamburg NM, et al
    Smoking is associated with increased risk of cardiovascular events, disease severity, and mortality among patients hospitalized for SARS-CoV-2 infections.
    PLoS One. 2022;17:e0270763.
    PubMed         Abstract available

  119. ABERESE-AKO M, Immurana M, Dalaba MA, Anumu FEY, et al
    The socio-economic and health effects of COVID-19 among rural and urban-slum dwellers in Ghana: A mixed methods approach.
    PLoS One. 2022;17:e0271551.
    PubMed         Abstract available

  120. GAO G, Lang R, Oxoby RJ, Mourali M, et al
    Drivers of downloading and reasons for not downloading COVID-19 contact tracing and exposure notification apps: A national cross-sectional survey.
    PLoS One. 2022;17:e0269783.
    PubMed         Abstract available

  121. OGDEN RS, Piovesan A
    How long was it for you? Memories of the duration of the UK covid-19 lockdown.
    PLoS One. 2022;17:e0271609.
    PubMed         Abstract available

  122. BURHOLT V, Balmer D, Frey R, Meha P, et al
    Health equity and wellbeing among older people's caregivers in New Zealand during COVID-19: Protocol for a qualitative study.
    PLoS One. 2022;17:e0271114.
    PubMed         Abstract available

  123. CASTANEDA-RIBEYRO A, Martins-Luna J, Verne E, Aguila-Luis MA, et al
    High prevalence and clinical characteristics of respiratory infection by human rhinovirus in children from Lima-Peru during years 2009-2010.
    PLoS One. 2022;17:e0271044.
    PubMed         Abstract available

  124. FATIMA S, Zafar A, Afzal H, Ejaz T, et al
    COVID-19 infection among vaccinated and unvaccinated: Does it make any difference?
    PLoS One. 2022;17:e0270485.
    PubMed         Abstract available

  125. BARNIKEL M, Alig AHS, Anton S, Arenz L, et al
    Follow-up lung ultrasound to monitor lung failure in COVID-19 ICU patients.
    PLoS One. 2022;17:e0271411.
    PubMed         Abstract available

  126. ELLISON B, Ocepek M, Kalaitzandonakes M
    U.S. household food acquisition behaviors during the COVID-19 pandemic.
    PLoS One. 2022;17:e0271522.
    PubMed         Abstract available

  127. SHAH R, Mohammed YN, Koehler TJ, Kaur J, et al
    Antiphospholipid antibodies and vitamin D deficiency in COVID-19 infection with and without venous or arterial thrombosis: A pilot case-control study.
    PLoS One. 2022;17:e0269466.
    PubMed         Abstract available

  128. BOYERS M, Garikipati S, Biggane A, Douglas E, et al
    Period poverty: The perceptions and experiences of impoverished women living in an inner-city area of Northwest England.
    PLoS One. 2022;17:e0269341.
    PubMed         Abstract available

  129. TRUJILLO-RODRIGUEZ M, Munoz-Muela E, Serna-Gallego A, Praena-Fernandez JM, et al
    Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients.
    PLoS One. 2022;17:e0269875.
    PubMed         Abstract available

  130. SINGH K, Cogan S, Elekes S, Murphy DM, et al
    SARS-CoV-2 spike and nucleocapsid proteins fail to activate human dendritic cells or gammadelta T cells.
    PLoS One. 2022;17:e0271463.
    PubMed         Abstract available

  131. YAMAMOTO R, Takemura R, Yamamoto A, Matsumura K, et al
    Threshold of increase in oxygen demand to predict mechanical ventilation use in novel coronavirus disease 2019: A retrospective cohort study incorporating restricted cubic spline regression.
    PLoS One. 2022;17:e0269876.
    PubMed         Abstract available

  132. WEBB WR, Thapa G, Tirnoveanu A, Kallu S, et al
    Single vs replicate Real-Time PCR SARS-CoV-2 testing: Lessons learned for effective pandemic management.
    PLoS One. 2022;17:e0269883.
    PubMed         Abstract available

  133. OTAKI F, Amir-Rad F, Al-Halabi M, Baqain Z, et al
    Self-reported adaptability among postgraduate dental learners and their instructors: Accelerated change induced by COVID-19.
    PLoS One. 2022;17:e0270420.
    PubMed         Abstract available

  134. HO TKK, Gwak J
    Feature-level ensemble approach for COVID-19 detection using chest X-ray images.
    PLoS One. 2022;17:e0268430.
    PubMed         Abstract available

  135. TANIGUCHI H, Ohya A, Yamagata H, Iwashita M, et al
    Prolonged mechanical ventilation in patients with severe COVID-19 is associated with serial modified-lung ultrasound scores: A single-centre cohort study.
    PLoS One. 2022;17:e0271391.
    PubMed         Abstract available

  136. SALAME H, Nawfal R, Kassem J, Mckey R, et al
    Utility of hematological and inflammatory biomarkers in predicting recovery in critical Covid-19 patients: Our experience in the largest Covid-19 treating center in Lebanon.
    PLoS One. 2022;17:e0271393.
    PubMed         Abstract available

  137. KUMAR CK, Balasubramanian R, Ongarello S, Carmona S, et al
    SARS-CoV-2 testing strategies for outbreak mitigation in vaccinated populations.
    PLoS One. 2022;17:e0271103.
    PubMed         Abstract available

  138. UJHELYI GOMEZ K, Corcoran R, Ring A, Hassan S, et al
    Characteristics of mental health stability during COVID-19: An online survey with people residing in a city region of the North West of England.
    PLoS One. 2022;17:e0266153.
    PubMed         Abstract available

  139. SRIVASRAV AK, Stollenwerk N, Bidaurrazaga Van-Dierdonck J, Mar J, et al
    Modeling the initial phase of COVID-19 epidemic: The role of age and disease severity in the Basque Country, Spain.
    PLoS One. 2022;17:e0267772.
    PubMed         Abstract available

  140. OHISHI T, Hishiki T, Baig MS, Rajpoot S, et al
    Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
    PLoS One. 2022;17:e0271112.
    PubMed         Abstract available

  141. GANESH T, Saravanan A, Mathivanan M
    Temples and bats in a homogeneous agriculture landscape: Importance of microhabitat availability, disturbance and land use for bat conservation.
    PLoS One. 2022;17:e0251771.
    PubMed         Abstract available

  142. KOIWA K, Wakashima K, Ikuta M, Asai K, et al
    Fear of COVID-19 infection and related factors in Japan: A comparison of college students, pregnant women, hospital nurses and the general public.
    PLoS One. 2022;17:e0271176.
    PubMed         Abstract available

  143. ALDHAHI MI, Alshehri MM, Alqahtani F, Alqahtani AS, et al
    A pilot study of the moderating effect of gender on the physical activity and fatigue severity among recovered COVID-19 patients.
    PLoS One. 2022;17:e0269954.
    PubMed         Abstract available

  144. LI L, Sullivan A, Musah A, Stavrianaki K, et al
    To Zoom or not to Zoom: A longitudinal study of UK population's activities during the COVID-19 pandemic.
    PLoS One. 2022;17:e0270207.
    PubMed         Abstract available

  145. HALL SM, Landaverde L, Gill CJ, Yee GM, et al
    Comparison of anterior nares CT values in asymptomatic and symptomatic individuals diagnosed with SARS-CoV-2 in a university screening program.
    PLoS One. 2022;17:e0270694.
    PubMed         Abstract available

  146. DE ALMEIDA L, Carelli PV, Cavalcanti NG, do Nascimento JD Jr, et al
    Quantifying political influence on COVID-19 fatality in Brazil.
    PLoS One. 2022;17:e0264293.
    PubMed         Abstract available

  147. VALLY Z, Helmy M
    The association between psychological burden related to COVID-19 and addictive social media use: Testing the mediational role of anxious affect.
    PLoS One. 2022;17:e0271332.
    PubMed         Abstract available

  148. CONSOLAZIO D, Sarti S, Terraneo M, Celata C, et al
    The impact of school closure intervention during the third wave of the COVID-19 pandemic in Italy: Evidence from the Milan area.
    PLoS One. 2022;17:e0271404.
    PubMed         Abstract available

  149. ZHU L, Marsh JW, Griffith MP, Collins K, et al
    Predictive model for severe COVID-19 using SARS-CoV-2 whole-genome sequencing and electronic health record data, March 2020-May 2021.
    PLoS One. 2022;17:e0271381.
    PubMed         Abstract available

  150. TEGEGNE MD, Girma S, Mengistu S, Mesfin T, et al
    Willingness to receive COVID-19 vaccine and associated factors among adult chronic patients. A cross-sectional study in Northwest Ethiopia.
    PLoS One. 2022;17:e0269942.
    PubMed         Abstract available

  151. CHA EJ, Jeon HJ
    The effect of COVID-19 pandemic on sleep-related problems in adults and elderly citizens: An infodemiology study using relative search volume data.
    PLoS One. 2022;17:e0271059.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  152. HUANG S, Fishell G
    In SARS-CoV-2, astrocytes are in it for the long haul.
    Proc Natl Acad Sci U S A. 2022;119:e2209130119.

  153. MARTNER A, Grauers Wiktorin H, Tornell A, Ringlander J, et al
    Transient and durable T cell reactivity after COVID-19.
    Proc Natl Acad Sci U S A. 2022;119:e2203659119.
    PubMed         Abstract available

  154. LIU Q, Wang H, Zhang H, Sui L, et al
    The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
    Proc Natl Acad Sci U S A. 2022;119:e2123065119.
    PubMed         Abstract available

  155. ANDREWS MG, Mukhtar T, Eze UC, Simoneau CR, et al
    Tropism of SARS-CoV-2 for human cortical astrocytes.
    Proc Natl Acad Sci U S A. 2022;119:e2122236119.
    PubMed         Abstract available

  156. SYED AM, Ciling A, Taha TY, Chen IP, et al
    Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
    Proc Natl Acad Sci U S A. 2022;119:e2200592119.
    PubMed         Abstract available

  157. MIKOLAJEK H, Weckener M, Brotzakis ZF, Huo J, et al
    Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes.
    Proc Natl Acad Sci U S A. 2022;119:e2205412119.
    PubMed         Abstract available

  158. TOWNSEND JP, Hassler HB, Sah P, Galvani AP, et al
    The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2022;119:e2204336119.
    PubMed         Abstract available

  159. FISMAN D
    Universal healthcare and the pandemic mortality gap.
    Proc Natl Acad Sci U S A. 2022;119:e2208032119.

  160. LONDAHL J, Alsved M
    Abrupt decreases in infectivity of SARS-CoV-2 in aerosols.
    Proc Natl Acad Sci U S A. 2022;119:e2208742119.

  161. RABB N, Bowers J, Glick D, Wilson KH, et al
    The influence of social norms varies with "others" groups: Evidence from COVID-19 vaccination intentions.
    Proc Natl Acad Sci U S A. 2022;119:e2118770119.
    PubMed         Abstract available


  162. STRAUS W, Rubin H
    COVID-19 vaccine safety monitoring in low and middle income countries - Time for a bold new approach.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00822.

  163. CARTANYA-HUESO A, Martinez-Sanchez JM, Carlos Martin-Sanchez J, Lidon-Moyano C, et al
    Relationship between double COVID-19 vaccine uptake and trust in effectiveness and safety of vaccination in general in 23 Member states of the European Union: an ecological study.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00820.
    PubMed         Abstract available

  164. SEYRAN M
    Artificial intelligence and clinical data suggest the T cell-mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00821.
    PubMed         Abstract available

  165. RONZANI P, Panizza F, Martini C, Savadori L, et al
    Countering vaccine hesitancy through medical expert endorsement.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00780.
    PubMed         Abstract available

  166. KOBAYASHI T, Nishina Y, Tomoi H, Harada K, et al
    Corowa-kun: A messenger app chatbot delivers COVID-19 vaccine information, Japan 2021.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00754.
    PubMed         Abstract available

  167. ABRAHAM N, Spruin S, Rossi T, Fireman B, et al
    Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00667.
    PubMed         Abstract available

  168. LIN K, Liu M, Bao L, Lv Q, et al
    Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00765.
    PubMed         Abstract available

  169. DIONATO FAV, Jalalizadeh M, Buosi K, Visacri MB, et al
    BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00803.
    PubMed         Abstract available

  170. SHINKAI M, Sonoyama T, Kamitani A, Shibata RY, et al
    Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
    Vaccine. 2022;40:4328-4333.
    PubMed         Abstract available

  171. GAMBRELL A, Sundaram M, Bednarczyk RA
    Estimating the number of US children susceptible to measles resulting from COVID-19-related vaccination coverage declines.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00782.
    PubMed         Abstract available

  172. ATWELL JE, Lutz CS, Sparrow EG, Feikin DR, et al
    Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Vaccine. 2022 Jun 17. pii: S0264-410X(22)00783.
    PubMed         Abstract available

  173. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    PubMed         Abstract available

  174. RAZZAGHI H, Yankey D, Vashist K, Lu PJ, et al
    COVID-19 vaccination coverage and intent among women aged 18-49 years by pregnancy status, United States, April-November 2021.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00779.
    PubMed         Abstract available

  175. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    PubMed         Abstract available

  176. UWAMINO Y, Kurafuji T, Takato K, Sakai A, et al
    Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00763.
    PubMed         Abstract available

  177. PHATARPHEKAR A, Vidyadhar Reddy GEC, Gokhale A, Karanam G, et al
    RelCoVax(R), a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00775.
    PubMed         Abstract available

  178. WALKER JL, Schultze A, Tazare J, Tamborska A, et al
    Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00757.
    PubMed         Abstract available

  179. ZHANG H, Li Y, Peng S, Jiang Y, et al
    The effect of health literacy on COVID-19 vaccine hesitancy among community population in China: The moderating role of stress.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00762.
    PubMed         Abstract available

  180. HALSTEAD IN, McKay RT, Lewis GJ
    COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00678.
    PubMed         Abstract available

  181. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    PubMed         Abstract available

  182. DAYTON L, Miller J, Strickland J, Davey-Rothwell M, et al
    A socio-ecological perspective on parents' intentions to vaccinate their children against COVID-19.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00736.
    PubMed         Abstract available

  183. EL-SHESHENY R, El Taweel A, Gomaa MR, Roshdy WH, et al
    Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00734.
    PubMed         Abstract available

  184. SHANMUGARAJ B, Khorattanakulchai N, Panapitakkul C, Malla A, et al
    Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00735.
    PubMed         Abstract available

  185. AB RAHMAN N, Lim MT, Lee FY, Lee SC, et al
    Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00700.
    PubMed         Abstract available

  186. SADOFF J, Le Gars M, Brandenburg B, Cardenas V, et al
    Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Vaccine. 2022;40:4403-4411.
    PubMed         Abstract available


  187. GE Y, Liu K, Chi Y, Zhu X, et al
    Exosomal microRNA expression profiles derived from A549 human lung cells in response to influenza A/H1N1pdm09 infection.
    Virology. 2022;574:9-17.
    PubMed         Abstract available

  188. LIM H, Kim SE, Lee YH, Hwang YH, et al
    Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein.
    Virology. 2022;573:118-123.
    PubMed         Abstract available

  189. ABDELKADER A, Elzemrany AA, El-Nadi M, Elsabbagh SA, et al
    In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing.
    Virology. 2022;573:96-110.
    PubMed         Abstract available

  190. AL-ZYOUD W, Haddad H
    Potential linear B-cells epitope change to a helix structure in the spike of Omicron 21L or BA.2 predicts increased SARS-CoV-2 antibodies evasion.
    Virology. 2022;573:84-95.
    PubMed         Abstract available

    Virus Res

  191. BHAT S, Rishi P, Chadha VD
    Understanding the epigenetic mechanisms in SARS CoV-2 infection and potential therapeutic approaches.
    Virus Res. 2022;318:198853.
    PubMed         Abstract available

  192. NUNES DBSM, Vieira C, Sa JM, Araujo GC, et al
    M2-2 gene as a new alternative molecular marker for phylogenetic, phylodynamic, and evolutionary studies of hRSV.
    Virus Res. 2022;318:198850.
    PubMed         Abstract available

  193. SHOKEEN K, Pandey S, Shah M, Kumar S, et al
    Insight towards the effect of the multi basic cleavage site of SARS-CoV-2 spike protein on cellular proteases.
    Virus Res. 2022;318:198845.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.